Veterinary Pain Management Market Worth 1.66 Billion Usd By 2023

By Author: Markets and Markets
Total Articles: 125
Comment this article

The veterinary pain management market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period. Factors such as growth in companion animal adoption, increasing number of veterinary practitioners and their rising income levels in developed economies, growing prevalence of animal disease causing pain and inflammation, and the rising adoption of pet insurance with growing animal health expenditure are expected to drive the growth of the market.

Browse 232 market data Tables and 45 Figures spread through 237 Pages and in-depth TOC on "Veterinary Pain Management Market"

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96167677

Veterinary hospitals & clinics are expected to be the largest distribution channel for veterinary pain management products in 2017.

Based on distribution channels, the veterinary pain management market is segmented into hospitals & clinics and pharmacies. In 2017, veterinary hospitals & clinics accounted for a larger market share than pharmacies primarily due to factors such ...
... as the increasing number of veterinary clinics and hospitals, growing ownership of companion animals, and increasing veterinary expenditure.

APAC is expected to grow at the highest CAGR during the forecast period.

Global veterinary pain management market has been studied for North America, Europe, Asia Pacific (APAC), Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in veterinary pain management market, primarily due to the significant growth in pet adoption, increasing awareness about animal health, and growing per capita animal health expenditure, especially in India and China.

The prominent players in the veterinary pain management market are Zoetis (US), Merck Animal Health (US), Elanco (US), Chanelle (Ireland), Boehringer Ingelheim (Germany), Vetoquinol (France), Bayer (Germany), Norbrook (Ireland), Ceva Santé Animale (France), K-Laser (US), Assisi (US), and Dechra Pharmaceuticals (UK). New product launches and acquisitions were the major strategies adopted by these payers to maintain their positions in the veterinary pain management market